劉利平博士為君圣泰創(chuàng)始人及首席執(zhí)行官，于1994年獲得南開大學(xué)高分子化學(xué)與物理博士學(xué)位，之后赴加拿大多倫多大學(xué)從事博士后研究。2009年劉博士獲得了美國約翰霍普金斯大學(xué)凱瑞商學(xué)院授予的MBA學(xué)位。從事新藥開發(fā)27年，領(lǐng)導(dǎo)并參與新藥開發(fā)項(xiàng)目近10個，擁有在美國成功完成新藥開發(fā)并批準(zhǔn)上市的經(jīng)驗(yàn)。在國際刊物發(fā)表論文20多篇，已獲得近40項(xiàng)國際專利授權(quán)。 劉利平博士2011年回國，創(chuàng)辦了君圣泰至今，主要從事新藥開發(fā)。君圣泰是一家立足中國，具有國際競爭力的原創(chuàng)新藥研發(fā)公司，聚焦未滿足的臨床需求。公司所開發(fā)的藥物擁有全球自主知識產(chǎn)權(quán)，專注于慢性肝病、消化系統(tǒng)和代謝疾病領(lǐng)域。 目前已完成多項(xiàng)臨床2期試驗(yàn)，試驗(yàn)結(jié)果在國際刊物發(fā)表，并在國際學(xué)術(shù)會議做大會報告。 公司獲得2項(xiàng)中國“十三五新藥創(chuàng)制重大專項(xiàng)”，并被FDA（美國食品藥品監(jiān)督管理局）授予2項(xiàng)FTD（快速審評通道資格認(rèn)定）、1項(xiàng)ODD（孤兒藥資格認(rèn)定）。 劉博士在行業(yè)及商界獲得多項(xiàng)殊榮，其中分別包括知名行業(yè)及商業(yè)媒體評選的“Biotech 15人”、“2021年值得關(guān)注的女性創(chuàng)業(yè)領(lǐng)袖”、“十大創(chuàng)新科學(xué)家”等。 ? Dr. Liping Liu is the founder and CEO of High Tide. She received her Ph.D. degree from Nankai University in 1994 and completed a postdoctoral fellowship training in? University of Toronto and Hospital for Sick Children in Canada.? Dr. Liu received her MBA degree from Carey Business School at Johns Hopkins University in 2009.? She has been engaged in new drug development for 27 years, led and participated in nearly 10 new drug development projects, and has the experience of successfully completing new drug development and marketing approval in the United States.? She has published more than 20 papers in international journals and obtained nearly 40 international patents. Dr. Liu returned to China in 2011 and founded High Tide Therapeutics Inc.? Headquartered in China, High Tide is a global clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders, with a focus on unmet medical needs. High Tide has completed several phase 2 clinical trials with results published in peer reviewed journals and presented at the international meetings. |